rs1555613206
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP2PP3PP5_Very_Strong
The NM_001042492.3(NF1):c.1721G>A(p.Ser574Asn) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 1/1 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S574R) has been classified as Likely pathogenic.
Frequency
Consequence
NM_001042492.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NF1 | NM_001042492.3 | c.1721G>A | p.Ser574Asn | missense_variant, splice_region_variant | Exon 15 of 58 | ENST00000358273.9 | NP_001035957.1 | |
NF1 | NM_001128147.3 | c.1721G>A | p.Arg574Lys | missense_variant | Exon 15 of 15 | NP_001121619.1 | ||
NF1 | NM_000267.3 | c.1721G>A | p.Ser574Asn | missense_variant, splice_region_variant | Exon 15 of 57 | NP_000258.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 29
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Neurofibromatosis, type 1 Pathogenic:3
- -
- -
This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 574 of the NF1 protein (p.Ser574Asn). This variant also falls at the last nucleotide of exon 15, which is part of the consensus splice site for this exon. This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with neurofibromatosis type 1 (PMID: 10712197, 16835897, 24232412; internal data). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 431976). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Cafe au lait spots, multiple Pathogenic:1
- -
not provided Pathogenic:1
Not observed in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Alters the last nucleotide of the exon and is predicted to destroy the splice donor site and result in aberrant splicing, although in the absence of functional evidence the actual effect of this sequence change is unknown; This variant is associated with the following publications: (PMID: 10712197, 16835897, 24232412, 29673180, 29685074, 25486365, 30014477) -
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Pathogenic:1
The c.1721G>A pathogenic mutation (also known as p.S574N), located in coding exon 15 of the NF1 gene, results from a G to A substitution at nucleotide position 1721. The amino acid change results in serine to asparagine at codon 574, an amino acid with highly similar properties. However, this change occurs in the last base pair of coding exon 15, which makes it likely to have some effect on normal mRNA splicing. This alteration has been previously reported in multiple individuals diagnosed with neurofibromatosis type 1 (Fahsold R et al, Am. J. Hum. Genet. 2000 Mar; 66(3):790-818; Lee MJ et al, Hum. Mutat. 2006 Aug; 27(8):832; Palma Milla C et al. Ann. Hum. Genet. 2018 Nov;82(6):425-436; Stella A et al. Genes (Basel) 2018 Apr;9(4)). This amino acid position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site; however, direct evidence is unavailable. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1721G>A variant (also known as p.S574N), located in coding exon 15 of the NF1 gene, results from a G to A substitution at nucleotide position 1721. The amino acid change results in serine to asparagine at codon 574, an amino acid with highly similar properties. However, this change occurs in the last base pair of coding exon 15, which makes it likely to have some effect on normal mRNA splicing. <span style="font-family:sans-serif,arial,verdana,trebuchet ms">This mutationhas been previously reported in multiple individuals diagnosedwithneurofibromatosistype1 (FahsoldR et al,Am. J. Hum. Genet. 2000 Mar; 66(3):790-818;Lee MJ et al,Hum.Mutat. 2006 Aug; 27(8):832)<span style="font-family:sans-serif,arial,verdana,trebuchet ms">.This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6500 samples (13000 alleles) with coverage at this position. Both the nucleotide andamino acid positions are highly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to abolish the native splice donor site; however, direct evidence is unavailable. In addition, this alteration is predicted to be tolerated by in silico analysis.Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at